静脉注射白消安/氟达拉滨联合美法仑或全身照射用于高危血液病的非亲缘脐血移植 - Suppr

I.v. BU/fludarabine plus melphalan or TBI in unrelated cord blood transplantation for high-risk hematological diseases.

作者信息

Yamamoto H, Uchida N, Matsuno N, Kon A, Nishida A, Ota H, Ikebe T, Nakano N, Ishiwata K, Araoka H, Takagi S, Tsuji M, Asano-Mori Y, Yamamoto G, Izutsu K, Masuoka K, Wake A, Yoneyama A, Makino S, Taniguchi S

机构信息

Department of Hematology, Toranomon Hospital, Tokyo, Japan.

1] Department of Hematology, Toranomon Hospital, Tokyo, Japan [2] Okinaka Memorial Institute for Medical Research, Tokyo, Japan.

出版信息

Bone Marrow Transplant. 2015 Apr;50(4):607-9. doi: 10.1038/bmt.2014.316. Epub 2015 Jan 26.

DOI:10.1038/bmt.2014.316

PMID:25621796

Abstract

摘要

相似文献

I.v. BU/fludarabine plus melphalan or TBI in unrelated cord blood transplantation for high-risk hematological diseases.

Bone Marrow Transplant. 2015 Apr;50(4):607-9. doi: 10.1038/bmt.2014.316. Epub 2015 Jan 26.

Hepatic injury following reduced intensity unrelated cord blood transplantation for adult patients with hematological diseases.

Biol Blood Marrow Transplant. 2006 Dec;12(12):1302-9. doi: 10.1016/j.bbmt.2006.07.013.

Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with Fludarabine-, Busulfan-, and Melphalan-Based Conditioning.

Biol Blood Marrow Transplant. 2016 Mar;22(3):499-504. doi: 10.1016/j.bbmt.2015.11.010. Epub 2015 Nov 21.

Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML.

Bone Marrow Transplant. 2006 Feb;37(3):263-9. doi: 10.1038/sj.bmt.1705240.

Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia.

Pediatr Blood Cancer. 2014 Apr;61(4):712-6. doi: 10.1002/pbc.24922. Epub 2013 Dec 30.

Influence of melphalan plus fludarabine-conditioning regimen in elderly patients aged ⩾55 years with hematological malignancies.

Bone Marrow Transplant. 2016 Jan;51(1):157-60. doi: 10.1038/bmt.2015.235. Epub 2015 Oct 5.

Feasibility of salvage cord blood transplantation following fludarabine, melphalan and low-dose TBI for graft rejection after hematopoietic stem cell transplantation.

Bone Marrow Transplant. 2016 Jul;51(7):985-7. doi: 10.1038/bmt.2016.16. Epub 2016 Feb 15.

Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Cancer. 2015 Apr 1;121(7):1048-55. doi: 10.1002/cncr.29163. Epub 2014 Nov 25.

Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents.

Pediatr Blood Cancer. 2015 May;62(5):883-9. doi: 10.1002/pbc.25389. Epub 2014 Dec 24.

Feasibility of salvage cord blood transplantation using a fludarabine, melphalan, and low-dose anti-thymocyte globulin conditioning regimen.

Int J Hematol. 2019 Apr;109(4):463-469. doi: 10.1007/s12185-019-02610-4. Epub 2019 Feb 8.

引用本文的文献

Examination of a nutritional treatment pathway according to pretreatment health status and stress levels of patients undergoing hematopoietic stem cell transplantation.

PLoS One. 2022 Aug 1;17(8):e0271728. doi: 10.1371/journal.pone.0271728. eCollection 2022.

Conditioning regimen with a 75% dose of standard busulfan/cyclophosphamide plus fludarabine before cord blood transplantation in older patients with AML and MDS.

Int J Hematol. 2019 Sep;110(3):347-354. doi: 10.1007/s12185-019-02688-w. Epub 2019 Jun 13.

Feasibility of salvage cord blood transplantation using a fludarabine, melphalan, and low-dose anti-thymocyte globulin conditioning regimen.

Int J Hematol. 2019 Apr;109(4):463-469. doi: 10.1007/s12185-019-02610-4. Epub 2019 Feb 8.

Successful Cord Blood Transplantation in a Werner Syndrome Patient with High-risk Myelodysplastic Syndrome.

Intern Med. 2019 Jan 1;58(1):109-113. doi: 10.2169/internalmedicine.0317-17. Epub 2018 Aug 24.

Hematopoietic stem cell transplantation for acute myeloid leukemia.

Int J Hematol. 2018 May;107(5):513-518. doi: 10.1007/s12185-018-2412-8. Epub 2018 Jan 27.

本文引用的文献

Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.

Biol Blood Marrow Transplant. 2011 Oct;17(10):1490-6. doi: 10.1016/j.bbmt.2011.02.007. Epub 2011 Feb 18.

Comorbidity index does not predict outcome in allogeneic myeloablative transplants conditioned with fludarabine/i.v. busulfan (FluBu4).

Bone Marrow Transplant. 2011 Oct;46(10):1326-30. doi: 10.1038/bmt.2010.293. Epub 2010 Dec 6.

Influence of comorbidities on transplant outcomes in patients aged 50 years or more after myeloablative conditioning incorporating fludarabine, BU and ATG.

Bone Marrow Transplant. 2011 Aug;46(8):1077-83. doi: 10.1038/bmt.2010.257. Epub 2010 Nov 8.

Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia.

J Clin Oncol. 2010 Jun 10;28(17):2859-67. doi: 10.1200/JCO.2009.27.1460. Epub 2010 May 3.

Busulfan in hematopoietic stem cell transplantation.

Biol Blood Marrow Transplant. 2009 May;15(5):523-36. doi: 10.1016/j.bbmt.2008.12.489. Epub 2009 Feb 12.

Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients.

Biol Blood Marrow Transplant. 2008 May;14(5):591-4. doi: 10.1016/j.bbmt.2008.02.016.

Umbilical cord blood transplantation after reduced-intensity conditioning for elderly patients with hematologic diseases.

Biol Blood Marrow Transplant. 2008 May;14(5):583-90. doi: 10.1016/j.bbmt.2008.03.003.

Successful engraftment of mismatched unrelated cord blood transplantation following reduced intensity preparative regimen using fludarabine and busulfan.

Ann Hematol. 2007 Jan;86(1):49-54. doi: 10.1007/s00277-006-0190-5. Epub 2006 Oct 12.

Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents.

Leukemia. 2006 Oct;20(10):1661-72. doi: 10.1038/sj.leu.2404334. Epub 2006 Jul 27.

Successful engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with advanced hematological diseases.

Clin Cancer Res. 2004 Jun 1;10(11):3586-92. doi: 10.1158/1078-0432.CCR-03-0754.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

I.v. BU/fludarabine plus melphalan or TBI in unrelated cord blood transplantation for high-risk hematological diseases.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献